Title | Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH, Zadra G, Penney KL, Mosquera JMiguel, Tyekucheva S, Mucci LA, Barbieri C, Loda M |
Journal | Mol Cancer Res |
Volume | 17 |
Issue | 2 |
Pagination | 446-456 |
Date Published | 2019 02 |
ISSN | 1557-3125 |
Keywords | Adenocarcinoma, Animals, Epigenomics, Humans, Male, Mice, Prostatic Neoplasms |
Abstract | Among prostate cancers containing Gleason pattern 4, cribriform morphology is associated with unfavorable clinicopathologic factors, but its genetic features and association with long-term outcomes are incompletely understood. In this study, genetic, transcriptional, and epigenetic features of invasive cribriform carcinoma (ICC) tumors were compared with non-cribriform Gleason 4 (NC4) in The Cancer Genome Atlas (TCGA) cohort. ICC ( = 164) had distinctive molecular features when compared with NC4 ( = 102). These include: (i) increased somatic copy number variations (SCNV), specifically deletions at 6q, 8p and 10q, which encompassed and losses and gains at 3q; (ii) increased and ; (iii) enrichment for and pathways by gene expression; and (iv) increased methylation of selected genes. In addition, when compared with the metastatic prostate cancer, ICC clustered more closely to metastatic prostate cancer than NC4. Validation in clinical cohorts and genomically annotated murine models confirmed the association with ( = 38) and ( = 818). The association of ICC with lethal disease was evaluated in the Health Professionals Follow-up Study (HPFS) and Physicians' Health Study (PHS) prospective prostate cancer cohorts (median follow-up, 13.4 years; = 818). Patients with ICC were more likely to develop lethal cancer [HR, 1.62; 95% confidence interval (CI), 1.05-2.49], independent from Gleason score (GS). IMPLICATIONS: ICC has a distinct molecular phenotype that resembles metastatic prostate cancer and is associated with progression to lethal disease. |
DOI | 10.1158/1541-7786.MCR-18-0440 |
Alternate Journal | Mol Cancer Res |
PubMed ID | 30333152 |
PubMed Central ID | PMC6359952 |
Grant List | P50 CA090381 / CA / NCI NIH HHS / United States R01 CA187918 / CA / NCI NIH HHS / United States U01 CA167552 / CA / NCI NIH HHS / United States R37 CA215040 / CA / NCI NIH HHS / United States P30 CA008748 / CA / NCI NIH HHS / United States R01 CA131945 / CA / NCI NIH HHS / United States K08 CA187417 / CA / NCI NIH HHS / United States P50 CA211024 / CA / NCI NIH HHS / United States UM1 CA167552 / CA / NCI NIH HHS / United States |
Related Lab:
Related Faculty:
Juan Miguel Mosquera, M.D. Massimo Loda, M.D.